Xiu-Shen Li1,2, Ke-Chao Nie1,2, Zhi-Hua Zheng1,2, Rui-Sheng Zhou1, Yu-Sheng Huang2, Zeng-Jie Ye1, Fan He1, Ying Tang3,4. 1. Guangzhou University of Chinese Medicine, 12 Airport Road, Baiyun District, Guangzhou, Guangdong, China. 2. Lingnan Medical Research Center of Guangzhou University of Chinese Medicine, 12 Airport Road, Baiyun District, Guangzhou, Guangdong, China. 3. Guangzhou University of Chinese Medicine, 12 Airport Road, Baiyun District, Guangzhou, Guangdong, China. tangying@gzucm.edu.cn. 4. Lingnan Medical Research Center of Guangzhou University of Chinese Medicine, 12 Airport Road, Baiyun District, Guangzhou, Guangdong, China. tangying@gzucm.edu.cn.
Abstract
BACKGROUND: Due to tumor heterogeneity, the diagnosis, treatment, and prognosis of patients with lung squamous cell carcinoma (LUSC) are difficult. DNA methylation is an important regulator of gene expression, which may help the diagnosis and therapy of patients with LUSC. METHODS: In this study, we collected the clinical information of LUSC patients in the Cancer Genome Atlas (TCGA) database and the relevant methylated sequences of the University of California Santa Cruz (UCSC) database to construct methylated subtypes and performed prognostic analysis. RESULTS: Nine hundred sixty-five potential independent prognosis methylation sites were finally identified and the genes were identified. Based on consensus clustering analysis, seven subtypes were identified by using 965 CpG sites and corresponding survival curves were plotted. The prognostic analysis model was constructed according to the methylation sites' information of the subtype with the best prognosis. Internal and external verifications were used to evaluate the prediction model. CONCLUSIONS: Models based on differences in DNA methylation levels may help to classify the molecular subtypes of LUSC patients, and provide more individualized treatment recommendations and prognostic assessments for different clinical subtypes. GNAS, FZD2, FZD10 are the core three genes that may be related to the prognosis of LUSC patients.
BACKGROUND: Due to tumor heterogeneity, the diagnosis, treatment, and prognosis of patients with lung squamous cell carcinoma (LUSC) are difficult. DNA methylation is an important regulator of gene expression, which may help the diagnosis and therapy of patients with LUSC. METHODS: In this study, we collected the clinical information of LUSC patients in the Cancer Genome Atlas (TCGA) database and the relevant methylated sequences of the University of California Santa Cruz (UCSC) database to construct methylated subtypes and performed prognostic analysis. RESULTS: Nine hundred sixty-five potential independent prognosis methylation sites were finally identified and the genes were identified. Based on consensus clustering analysis, seven subtypes were identified by using 965 CpG sites and corresponding survival curves were plotted. The prognostic analysis model was constructed according to the methylation sites' information of the subtype with the best prognosis. Internal and external verifications were used to evaluate the prediction model. CONCLUSIONS: Models based on differences in DNA methylation levels may help to classify the molecular subtypes of LUSC patients, and provide more individualized treatment recommendations and prognostic assessments for different clinical subtypes. GNAS, FZD2, FZD10 are the core three genes that may be related to the prognosis of LUSC patients.
Authors: Abdurrahman Kadayifci; Mustafa Atar; Jessica L Wang; David G Forcione; Brenna W Casey; Martha B Pitman; William R Brugge Journal: Dig Endosc Date: 2016-10-04 Impact factor: 7.559